Used as a potent inhibitor in targeted cancer therapies, particularly in the treatment of certain tyrosine kinase-driven tumors. It interferes with signaling pathways involved in cell proliferation and survival by selectively inhibiting specific mutant forms of epidermal growth factor receptor (EGFR), including T790M and C797S mutations commonly found in non-small cell lung cancer (NSCLC). Its structure allows for improved binding affinity and selectivity, enhancing antitumor activity while reducing off-target effects. This compound is valuable in overcoming resistance to earlier generations of EGFR inhibitors, making it a key candidate in next-generation oncology drug development.